Neoplastic meningitis: A guide to diagnosis and treatment

CNS Drugs

Volumn 10, Issue 1, 1998, Pages 25-41

  Chamberlain, Marc C ^a   Kormanik, Patty A ^b  

^a KAISER PERMANENTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CYTARABINE; FOLINIC ACID; GADOLINIUM; METHOTREXATE; THIOTEPA;

BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CARCINOMATOUS MENINGITIS; CEREBROSPINAL FLUID EXAMINATION; CEREBROSPINAL FLUID FLOW; CEREBROSPINAL FLUID SHUNTING; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; HUMAN; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; INTRASPINAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LEPTOMENINX; MYELOGRAPHY; NEUROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW;

EID: 0031813882     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-199810010-00003     Document Type: Review

References (88)

1. Olson M, Chernik N, Posner J. Infiltration of the leptomeninges by systemic cancer: a clinical and pathologic study. Arch Neurol 1974; 30: 122-37
2. Kokkoris C. Leptomeningeal carcinomatosis: how does cancer reach the pia-arachnoid? Cancer 1983; 51: 154-60
3. Gonzalez-Vitale J, Garcia-Bunuel R. Meningeal carcinomatosis. Cancer 1976; 37: 2906-11
4. Wasserstrom W, Glass J, Posner J. Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. Cancer 1982; 49: 759-72
5. 111Indium-DTPA CSF flow studies. Neurology 1991; 41: 1765-9
6. Little J, Dale A, Okazaki H. Meningeal carcinomatosis: clinical manifestations. Arch Ncurol 1974; 30: 138-43
7. Shapiro W, Posner J, Ushio Y, et al. Treatment of meningeal neoplasms. Cancer Treat Rep 1977; 61: 733-43
8. Theodore WH, Gendelman S. Meningeal carcinomatosis. Arch Neurol 1981; 38: 696-9
9. Kaplan J, DeSouza T, Farkash A, et al. Leptomeningeal metastases: comparison of clinical features and laboratory data of solid tumors, lymphomas and leukemias. J Neurooncol 1990; 92: 25-9
10. Posner J, Chernik N. Intracranial metastases from systemic cancer. Adv Neurol 1978; 19: 579-91
11. Packer R, Siegel K, Sutton L, et al. Leptomeningeal dissemination of primary central nervous system: tumors of childhood. Ann Neurol 1985; 18: 217-21
12. Yung W, Horten B, Shapiro W. Meningeal gliomatosis: a review of 12 cases. Ann Neurol 1980; 8: 605-8
13. Awad I, Bay J, Rogers L. Leptomeningeal metastasis from supratentorial malignant gliomas. Neurosurgery 1986; 19: 247-51
14. Civitello L, Packer R, Rorke L, et al. Leptomeningeal dissemination of low-grade gliomas in childhood. Neurology 1988; 38: 562-6
15. Chamberlain M, Dirr L. Involved field radiotherapy and intraommaya methotrexate/ara-C in patients with AIDS-related lymphomatous meningitis. J Clin Oncol 1993; 11: 1978-84
16. Rosen S, Aisner J, Makuch R, et al. Carcinomatous leptomeningitis in small cell lung cancer: a clinicopathologic review of the National Cancer Institute Experience. Am J Med 1982; 61: 45-53
17. Glass J, Melamed M, Chernik N, et al. Malignant cells in cerebrospinal fluid (CSF): the meaning of a positive CSF cytology. Neurology 1979; 29: 1369-75
18. Murray J, Greco F, Wolff S, et al. Neoplastic meningitis: marked variations of cerebrospinal fluid composition in the absence of extradural block. Am J Med 1983; 75: 289-94
19. Schold S, Wasserstrom W, Fleisher M, et al. Cerebrospinal fluid biochemical markers of central nervous system metastases. Ann Neurol 1980; 85: 597-604
20. 2-microglobulin in lymphoproliferative and other neoplastic diseases of the central nervous system. Arch Neurol 1987; 44: 915-20
21. Klee G, Tallman R, Goellner J, et al. Elevation of carcinoembryonic antigen in cerebrospinal fluid among patients with meningeal carcinomatosis. Mayo Clin Proc 1986; 6: 9-13
22. Schipper H, Bardosi A, Jacobi C, et al. Meningeal carcinomatosis origin of local IgG production in the CSF. Neurology 1988; 38: 413-6
23. Newton H, Fleisher M, Schwartz M, et al. Glucosephosphate isomerase as a CSF marker for leptomeningeal metastasis. Neurology 1991; 41: 395-8
24. Malkin M, Posner J. Perspectives and commentaries: cerebrospinal fluid tumor markers for the diagnosis and management of leptomeningeal metastases. Eur J Cancer Clin Oncol 1986; 22: 387-92
25. Chamberlain MC, Kormanik PA. Cytologically negative carcinomatous meningitis: usefulness of CSF biochemical markers. Neurology 1998; 50: 1173-5
26. Cibas E, Malkin M, Posner J, et al. Detection of DNA abnormalities by flow cytometry in cells from cerebrospinal fluid. Am J Clin Pathol 1987; 88: 570-7
27. Grossman S, Moynihan T. Neurologic complications of systemic cancer: neoplastic meningitis. Neurol Clin 1991; 9: 843-56
28. Recht L. Neurologic complications of systemic cancer: neurologic complications of systemic lymphoma. Neurol Clin 1991; 9: 1001-15
29. Walker R. Neurologic complications of systemic cancer: neurologic complications of leukemia. Neurol Clin 1991; 9: 989-99
30. Chamberlain M, Sandy A, Press G. Leptomeningeal metastasis: a comparison of gadolinium-enhanced MR and contrast-enhanced CT of the brain. Neurology 1990; 40: 435-8
31. Jaeckle K, Krol G, Posner J. Evolution of computed tomographic abnormalities in leptomeningeal metastases. Ann Neurol 1985; 17: 85-9
32. Lee Y, Glass J, Geoffray A, et al. Cranial computed tomographic abnormalities in leptomeningeal metastasis. AJR Am J Roentgenol 1984; 143: 1035-9
33. Ascherl Jr G, Hilal S, Brisman R. Computed tomography of disseminated meningeal and ependymal malignant neoplasms. Neurology 1981; 31: 567-74
34. Sze G, Soletsky S, Bronen R, et al. MR imaging of the cranial meninges with emphasis on contrast enhancements and meningeal carcinomatosis. AJNR Am J Neuroradiol 1989; 10: 965-75
35. Kim K, Ho S, Weinberg P, et al. Spinal leptomeningeal infiltration by systemic cancer myelographic features. AJR Am J Roentgenol 1982; 139: 361-5
36. Krol G, Sze G, Malkin M, et al. MR of cranial and spinal meningeal carcinomatosis comparison with CT and myelography. AJNR Am J Neuroradiol 1988; 9: 709-14
37. Kramer E, Rafto S, Packer R, et al. Comparison of myelography with CT follow-up versus gadolinium MRI for subarachnoid metastatic disease in children. Neurology 1991; 41: 46-50
38. Sze G, Abramson A, Krol G, et al. Gadolinium-DTPA in the evaluation of intradural extramedullary spinal disease. AJNR Am J Neuroradiol 1988; 9: 153-63
39. Lim V, Sobel D, Zyroff J. Spinal cord pial metastases MR imaging with gadopentetate dimeglumine. AJNR Am J Neuroradiol 1990; 11: 975-82
40. Pedersen A, Paulson O, Gyldensted C. Metrizamide myelography in patients with small cell carcinoma of the lung suspected of meningeal carcinomatosis. J Neurooncol 1985; 3: 85-9
41. Wiener M, Boyko O, Friedman H, et al. False-positive spinal MR findings for subarachnoid spread of primary CNS tumor in postoperative pediatric patients. AJNR Am J Neuroradiol 1990; 11: 1100-3
42. Rippe D, Boyko O, Friedman H, et al. Gd-DTPA-enhanced MR imaging of leptomeningeal spread of primary CNS tumor in children. AJNR Am J Neuroradiol 1990; 11: 329-32
43. Chamberlain MC. Comparative spine imaging in leptomeningeal metastases. J Neurooncol 1995; 23: 233-8
44. Larson S, Johnston G, Ommaya A, et al. The radionuclide ventriculogram. JAMA 1973; 224: 853-7
45. Di Chiro G, Hammock M, Bleyer A. Spinal descent of cerebrospinal fluid in man. Neurology 1976; 26: 1-8
46. Lyons M, Meyer F. Cerebrospinal fluid physiology and the management of increased intracranial pressure. Mayo Clin Proc 1990; 65: 684-707
47. 111Indium-DTPA CSF flow studies. J Child Neurol 1994; 9: 150-4
48. 111Indium-DTPA CSF flow studies in leptomeningeal metastasis. J Neurooncol 1995; 25: 135-41
49. Blasberg R, Patlak C, Fenstermacher J. Intrathecal chemotherapy brain tissue profiles after ventriculo-cisternal perfusion. Pharm Exp Ther 1975; 195: 73-83
50. Slevin M, Piall E, Aherne G, et al. Effect of dose and schedule on pharmacokinetics of high-dose cytosine arabinoside in plasma and cerebrospinal fluid. J Clin Oncol 1983; 1: 546-51
51. Lopez J, Nassif E, Vannicola P, et al. Central nervous system pharmacokinetics of high-dose cytosine arabinoside. J Neurooncol 1985; 3: 119-24
52. Ackland S, Schilsky R. High-dose methotrexate: a critical reappraisal. J Clin Oncol 1987; 5: 2017-31
53. Balis F, Poplack D. Central nervous system pharmacology of antileukemic drugs. Am J Pediatr Hematol Oncol 1989; 11: 74-86
54. Collins J. Pharmacokinetics of intraventricular administration. J Neurooncol 1983; 1: 283-91
55. Grant R, Naylor B, Greeberg HS, et al. Clinical outcome in aggressively treated meningeal carcinomatosis. Arch Neurol 1994; 51: 457-61
56. Siegal T, Lassos A, Pfeffer MR. Leptomeningeal metastases: analysis of 31 patients with sustained off-therapy response following combined-modality therapy. Neurology 1994; 44: 1463-9
57. Boogerd W, Hart AAM, Van der Sande JJ, et al. Meningeal carcinomatosis in breast cancer: prognostic factors and influence of treatment. Cancer 1991; 67: 1685-95
58. Fizazi K, Asselain B, Vincent-Salomon A, et al. Meningeal carcinomatosis in patients with breast carcinoma. Cancer 1996; 77 (7): 1315-23
59. Shapiro W, Young D, Mehta B. Methotrexate distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. N Engl J Med 1975; 293: 161-6
60. Bleyer W. Current status of intrathecal chemotherapy for human meningeal neoplasms. NCI Monogr 1977; 46: 171-8
61. Gutin P, Weiss H, Wiernik P, et al. Intrathecal N, N′, N′-triethylenethiophosphoramide [thio-TEPA (NSC 6369)] in the treatment of malignant meningeal disease. Phase I-II study. Cancer 1976; 38: 1471-5
62. Gutin P, Levi J, Wiernik P, et al. Treatment of malignant meningeal disease with intrathecal thio-TEPA: a phase II study. Cancer Treat Rep 1977; 61: 885-7
63. Fulton D, Levin V, Gutin P, et al. Intrathecal cytosine arabinoside for the treatment of meningeal metastases from malignant brain tumors and systemic tumors. Cancer Chemother Pharmacol 1982; 8: 285-91
64. Strong J, Collins J, Lester C, et al. Pharmacokinetics of intraventricular and intravenous N, N′, N″-triethylenethiophosphoramide (thiotepa) in rhesus monkeys and humans. Cancer Res 1986; 46: 6101-4
65. Jaeckle K, Lukes S, Krown S, et al. Phase I study of intraventricularly administered human interferon in patients with leptomeningeal tumor. Ann Neurol 1983; 14: 138-9
66. Blacklock J, Grimm E, Loudon W, et al. CNS tumors 362 intraventricular interleukin-2 in the treatment of leptomeningeal melanomatosis: phase I clinical trial and kinetic study [abstract]. Proceedings of the American Society of Clinical Oncologists 1989; 8: 93
67. 1731I monoclonal antibodies in the therapy of leptomeningeal tumors. Cancer 1988; 61; 857-68
68. Berg S, Balis F, Zimm S, et al. Phase I/II trial and pharmacokinetics of intrathecal diaziquone in refractory meningeal malignancies. J Clin Oncol 1992; 10: 143-8
69. Arndt C, Colvin O, Balis F, et al. Intrathecal administration of 4-hydroperoxycyclophosphamide in rhesus monkeys. Cancer Res 1987; 47: 5932-4
70. Chamberlain M, Khatibi S, Kim J, et al. Leptomeningeal metastasis with intraventricular Depo/ara-C: a phase I study. Arch Neurol 1993; 50: 261-4
71. Kim S, Chatelut E, Kim J, et al. Extended CSF cytarabine exposure following intrathecal administration of DTC 101. J Clin Oncol 1993; 11: 2186-93
72. Giannone L, Greco F, Hainsworth J. Combination intraventricular chemotherapy for meningeal neoplasia. J Clin Oncol 1986; 4: 68-73
73. Hitchens R, Bell D, Woods R, et al. A prospective randomized trial of single-agent versus combination chemotherapy in meningeal carcinomatosis. J Clin Oncol 1987; 5: 1655-62
74. Grossman SA, Finkelstein DM, Ruckdeschel JC, et al. Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. J Clin Oncol 1993; 11: 561-9
75. Chamberlain MC, Kormanik PA. Complications associated with intraventricular chemotherapy in patients with leptomeningeal metastases. J Neurosurg 1997; 87: 694-9
76. Lishner M, Perrin R, Feld R, et al. Complications associated with ommaya reservoirs in patients with cancer. Arch Intern Med 1990; 150: 173-6
77. Chamberlain MC, Kormanik P. Leptomeningeal metastases due to melanoma: combined modality therapy. Int J Oncol 1996; 9: 505-10
78. Chamberlain MC, Kormanik PA. Carcinomatous meningitis secondary to breast cancer: combined modality therapy. J Neurooncol 1997; 35; 55-64
79. Glantz M, Hall WA, Cole BF, et al. Diagnosis, management, and survival of patients with leptomeningeal cancer based on cerebrospinal fluid-flow studies. Cancer 1995; 75: 2919-34
80. Balm M, Hammack J. Leptomeningeal carcinomatosis. Arch Neurol 1996; 53: 626-32
81. 111Indium-DTPA CSF flow studies. Neurology 1996; 46 (6): 1674-7
82. Chamberlain MC, Kormanik PA. Prognostic significance of co-existent bulky metastatic CNS disease in patients with leptomeningeal metastases. Arch Neurol 1997; 54: 1364-8
83. Freilich RJ, Krol G, DeAngelis LM. Neuroimaging and cerebrospinal fluid cytology in the diagnosis of leptomeningeal metastasis. Ann Neurol 1995; 38: 51-7
84. Chamberlain MC, Kormanik PA. Carcinomatous meningitis secondary to non-small cell lung cancer: combined modality therapy. Arch Neurol 1998; 55: 506-12
85. Chamberlain MC, Kormanik PA. Non-AIDS related lymphomatous meningitis: combined modality therapy. Neurology 1997; 49: 1728-31
86. Chamberlain MC, Kormanik PA. Lymphomatous meningitis in immunocompromised patients: combined modality therapy. Oncol Rep 1998; 5 (2): 521-5
87. Dedrick R, Zaharko D, Bender R, et al. Pharmacokinetic considerations on resistance to anticancer drugs. Cancer Chemother Rep 1975; 59: 795-804
88. Grossman S, Trump D, Chen D, et al. Cerebrospinal fluid flow abnormalities in patients with neoplastic meningitis. Am J Med 1982; 73: 641-7